tbuckley/cabot-search huggingface dataset:
Abstract 521: Connexin 43 and E-cadherin modulate prostate cancer cell migration
Authors: Abdulaziz Aloliqi, Ao Zhang, Adina Brett-Morris, Justin Lathia, Gail C. Fraizer
Journal: Cancer Research (2015)

Abstract Connexins play a major role in cell-cell communication and form a bidirectional signaling pathway to assemble gap junctions and, along with cadherins, alter cell behaviors, such as motility. To assess the effect of Connexin 43 (Cx43) on migration of prostate cancer cells we performed two types of migration assays using shRNA Cx43 transfected PC3 cells with suppressed Cx 43. Wound healing and transwell chamber assays were used to assess the migratory potential of stably transfected shCx43-PC3 cells. When we reduced Cx 43 we saw approximately a two-fold reduction in migration of shCx43 transfected PC3 cells compared to those transfected with scramble controls. Since suppression of Cx43 reduced migration of the highly migratory PC3 cells, we wondered whether this reflected a partial loss of mesenchymal traits (e.g., motility) and acquisition of epithelial markers, (e.g.,E-cadherin expression). Using quantitative RT-PCR, E-cadherin expression was assessed in shCx43-PC3 and scramble control cells. Suppression of Cx43 increased E-cadherin mRNA levels 5-fold or greater in shCx43-PC3 cells than in scramble control cells. An alternative approach used to transcriptionally up-regulate E-cadherin mRNA in PC3 cells (via suppression of a transcriptional repressor) resulted in a similar approximately 2.5-fold suppression of migration as measured by wound healing and transwell chamber assays. Thus, an inverse relation of Cx 43 and E-cadherin was observed in prostate cancer cells and alterations in either led to aberrant migration. These results were consistent with our hypothesis that differential connexin expression in prostate cancer cells contributes to different metastatic potential. To correlate differential connexin subunit expression with migratory potential, we quantified gene expression of 13 different Connexin subunits in non-invasive LNCaP and in invasive PC3 cells using qRTPCR. In LNCaP cells we observed low levels of Cx43 along with high levels of Cx32 and E-cadherin expression and the converse in PC3 cells. Overall, these results suggest that reducing high levels of Cx43, associated with enhanced E-cadherin expression and reduced migratory behavior could potentially block lethal metastatic tumor progression of prostate cancer cells. Citation Format: Abdulaziz Aloliqi, Ao Zhang, Adina Brett-Morris, Justin Lathia, Gail C. Fraizer. Connexin 43 and E-cadherin modulate prostate cancer cell migration. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 521. doi:10.1158/1538-7445.AM2015-521
Repeated failure to report female genital mutilation should be a criminal offence, MPs say
Authors: Clare Dyer
Journal: BMJ (2016)

An influential committee of MPs has called for harsher penalties, beyond the existing professional disciplinary sanctions, against health professionals who do not report cases of female genital mutilation (FGM) to police.1

In its latest report on FGM, the House of Commons Home Affairs Committee repeated its predecessor committee’s call in a 2014 report to make intentional or repeated failures to report such abuse a criminal offence.2

Although …
Predictors of patient misunderstanding of the goals of care at initiation of chemotherapy.
Authors: I. T. Lennes, J. S. Temel, C. Hoedt, P. J. Saylor, T. M. Ortiz, S. Admane, E. B. Lamont
Journal: Journal of Clinical Oncology (2010)

9038 Background: All patients should be apprised of the risks of treatment before starting chemotherapy. According to the ASCO QOPI core measures, providers should also discuss the associated goals of care (GOC) at the time of consent discussion. We sought to determine if attributes of patients and initial patient-MD encounters were associated with subsequent patient-MD concordance regarding GOC. Methods: At a single academic medical center, we surveyed 137 consecutive patients within 30 days of their consent for first chemotherapy to assess their understanding of the GOC (i.e., curative vs. non-curative). The patients had solid tumors and represented all stages of disease. The survey was designed to assess patient understanding of the GOC and to measure several areas that are plausibly relevant to this understanding. We compared this to the GOC documented by their treating oncologists in the institution's chemotherapy order entry system (required). Results: The survey response rate was 91% (125/137). Using the MD GOC as the gold- standard, we found that only 76% (95/125) of patient-MD pairs were concordant regarding the GOC; 16% (20/125) of patients erroneously believed their GOC was curative; and 8% (10/125) erroneously believed their GOC was not curative. In a multivariable logistic regression that controlled for patient demographics and other patient factors, we found that patients greater than 65 years of age had an almost 80% lower odds (OR 0.21, 95% CI: 0.08-0.55) of concordance compared to younger patients; that patients for whom English was not their native language also had an almost 80% lower odds (OR 0.22, 95% CI: 0.05-0.93) of concordance compared to native English speakers; and that patients who received printed materials during the patient-MD consent process had almost three times higher odds (OR 2.97, 95% CI: 1.13-7.79) of concordance compared to those not receiving such materials. Conclusions: Patient misunderstanding of MD's GOC was substantial. Key predictors of discordance included factors potentially amenable to interventions at the time of patient chemotherapy consent including provision of printed material and use of communication aids targeted at elderly and non-native English speaking patients. No significant financial relationships to disclose.
Clinical and Angiographic Predictors of Death or Myocardial Infarction in Diabetics with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: An ACUITY Subanalysis
Authors: Kenji Goto, Alexandra J Lansky, Ecatarina Cristea, Martin Fahy, Frederick Feit, Magnus E Ohman, Harvey D White, Karen P Alexander, Michel E Bertrand, Walter Desmet, Martial Hamon, Steven Manoukian, Ramin Ebrahimi, Carles Pollack, Michael J Attubato, Roxana Mehran, Gregg W Stone
Journal: Journal of the American College of Cardiology (2009)
Reframing Prevention in the Era of Health Reform
Authors: Howard K. Koh, Rahul Rajkumar, John E. McDonough
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Screening reduced cervical cancer deaths by more than two thirds, UK study finds
Authors: Susan Mayor
Journal: BMJ (2016)

Regular cervical screening at least every five years is associated with a 67% reduction in cervical cancer that translates into a 70% reduction in deaths from the disease, a study has found.1

The study, reported in the British Journal of Cancer , is the first to assess the impact of screening on deaths from cervical cancer by using information …
Quality of Life Analysis in Patients with Kras Wild-Type Metastatic Colorectal Cancer Treated with First-Line Folfiri Plus Cetuximab
Authors: I. Láng, C. Köhne, G. Folprecht, P. Rougier, D. Curran, E. Hitre, U. Sartorius, I. Griebsch, E. Van Cutsem
Journal: Annals of Oncology (2012)
Esophagobronchial fistula closed by a cardiac septal occluder device
Authors: Ignacio Fernandez-Urien, Roman Lezaun, Maria Hernández, Baltasar Lainez, Catia Leitão, Juan Vila
Journal: Endoscopy (2016)

Esophageal–respiratory tract fistulas are rare but life-threatening conditions [1]. They may be congenital or secondary to esophageal and bronchogenic neoplasms, radiotherapy, or surgery. Currently, there is a changing paradigm for their management with surgery being replaced by conservative approaches including endoscopic therapy [2]. In fact, fully covered self-expandable metal stents (SEMSs) are currently the preferred therapeutic option; however, their clinical success rate is still poor and the rate of fistula reopening remains high [1] [2]. This has led to the appearance of therapeutic alternatives, such as the use of cardiac septal closure -devices and others [3] [4] [5].
S123 Coronary atherosclerosis detected at elective angiography is more severe in people with COPD than in those without: Abstract S123 Table 1
Authors: SV Ruickbie, A Prasad, PW Jones, EH Baker
Journal: Thorax (2015)

<h3>Introduction</h3> Coronary artery disease (CAD) affects 16–53% people with chronic obstructive pulmonary disease (COPD) and is the cause of death in ~25% (Smith and Wrobel. Int J COPD. 2014;9:871–888). People with COPD have both high prevalence of cardiovascular risk factors and increased systemic inflammation and oxidative stress that can drive atherosclerosis. We therefore tested the hypothesis that patients with COPD have more extensive coronary artery disease compared to those without. <h3>Methods</h3> All patients attending for elective coronary angiography March–July 2015 were invited to take part in a cross-sectional, observational study. Participants who gave consent underwent clinical assessment and spirometry prior to the procedure. COPD was defined as FEV<sub>1</sub>/FVC 10 pack-year smoking history. CAD burden was quantified from the angiogram using the Gensini score (Neeland <i>et al</i>. Am Heart J 2012;164:547–552). A single rater (Professor of Interventional Cardiology), blinded to clinical diagnosis, determined number and severity of lesions. Blinded repeats were performed and ratings compared to clinical reports to ensure reliability. A nonlinear score was assigned to each lesion based on severity of stenosis and a multiplier applied depending on lesion location in the coronary tree. Lesion scores were summed to derive Gensini score which was log-transformed for analysis. <h3>Results</h3> 249 of 294 (85%) people approached took part, 46 (19%) had COPD. The Table 1 compares demographic, respiratory disease-related and cardiovascular risk factors between people with and without COPD. Gensini score was higher in COPD patients (22.5 (8.5–46.0)) than in those without (12.5 (6.0–26.8), p = 0.04), indicating greater burden of coronary atheroma. COPD patients had more circumflex lesions and tended to have more lesions in the right coronary artery and in total than those without. <h3>Conclusions</h3> People with COPD have more severe coronary artery disease than those without. This analysis cannot determine whether this was due to the presence of COPD or the fact that patients with CAD and COPD had much greater cigarette smoke exposure than CAD patients without COPD.
Evidence for Premature Aging of (Clonal but also) Non-Clonal Hematopoietic Stem Cells in Patients with Acute Myeloid Leukemia (AML)
Authors: Martina Crysandt, Monica S.V. Ferreira, Patrick Ziegler, Sebastian Hummel, Julian Kaufmann, Stefan Wilop, Edgar Jost, Wolfgang Wagner, Tim H. Brummendorf, Fabian Beier
Journal: Blood (2014)
Clinical Course and Management of Surgical Emergency in a Severe Hemophilia a Patient Under Weekly Subcutaneous Administration of a Bispecific Antibody to Factors IXa and X (ACE910)
Authors: Takeshi Kanematsu, Nobuaki Suzuki, Naomi Sanda, Mika Ogawa, Mayuko Kishimoto, Atsuo Suzuki, Hitoshi Kiyoi, Ryu Kasai, Tadashi Matsushita
Journal: Blood (2015)
GPS-friendly exercise with Runmeter
Authors: Patrick S Tucker, Thomas M Doering
Journal: British Journal of Sports Medicine (2016)

Runmeter GPS Pedometer.

Health and fitness.

Requires iOS 7.0 or later.

Free with In-App purchases.

Runmeter GPS Pedometer is an application designed to help users monitor and record variables related to any type of exercise that may make use of GPS technology such as walking, jogging or cycling. To accomplish this, Runmeter uses the Apple M7 motion coprocessor to collect sensor data from integrated accelerometers, gyroscopes and compasses.

In its free version, Runmeter offers limited but useful features that are similar to the core features one might find in similar apps. Examples of this include GPS-based maps and exercise-related graphs. However, upgrading to the ‘Elite’ version of the app (US$9.99) offers considerably more …
Computer quantification of airway collapse on forced expiratory flow-volume loops to predict the presence of emphysema
Authors: Marko Topalovic, Vasileios Exadaktylos, Anneleen Peeters, Johan Coolen, Martijn Hemeryck, Pieter Slagmolen, Karl Janssens, Daniel Berckmans, Marc Decramer, Wim Janssens
Journal: American Journal of Respiratory and Critical Care Medicine (2013)
Myeloablative radioimmunotherapy with Re-188-labeled anti-CD66a,b,c,e-antibody for conditioning of high-risk ALL and CML patients prior to stem cell transplantation
Authors: I Buchmann, SN Reske, J Kotzerke, H Martin, G Glatting, U Seitz, Dirk Rattat, M Wiesneth, D Dohr, A Buck, L Bergmann, H Doehner, S von Harsdorf, M Stefanic, C Duncker, D Bunjes
Journal: Blood (2000)
P3-096: Phase II study of erlotinib in chemo–naïve women with advanced pulmonary adenocarcinoma.
Authors: David M. Jackman, Neal Lindeman, Joan Lucca, Linda K. Morse, Michael S. Rabin, J.P. Marcoux, Mark S. Huberman, Bruce E. Johnson, Pasi A. Janne
Journal: Journal of Thoracic Oncology (2007)
P3-100: Effect of gefitinib on survival of patients with pulmonary adenocarcinoma who had recurred after surgery in case controlled study.
Authors: Katayama Tatsuya, Ishiguro Futoshi, Onozato Ryoichi, Kosaka Takayuki, Fukui Takayuki, Mori Shoichi, Hatooka Shunzo, Shinoda Masayuki, Matsuo Keitaro, Yatabe Yasushi, Mitsudomi Tetsuya
Journal: Journal of Thoracic Oncology (2007)
The impact of cytogenetic features and clonality on the prognosis of patients with poor-risk MDS and secondary AML treated with intensive chemotherapy and stem cell transplantation: A joint study of the EORTC, EBMT, SAKK, HOVON and GIMEMA leukemia groups
Authors: T de Witte, S Suciu, J van Dijk, Michel Delforge, Anne Hagemeijer-Hausman, M Jotterand-Bellomo, I Tigaud, A Belhabri, C Aul, M Avaido, D Selleslag, H Schouten, A Ferrant, S Amadori, P Muus, O Anak, A Gratwohl, R Willemze
Journal: Blood (2000)
A Novel Prognostic Model To Predict Relapse After Allogeneic Stem Cell Transplantation For Myelodysplastic Syndromes
Authors: Saad Sirop Kenderian, Mark R Litzow, Aref Al-Kali, Dennis A Gastineau, Shahrukh K Hashmi, William J Hogan, Mrinal M Patnaik
Journal: Blood (2013)
Prevention of Chronic GvHD after HLA-Identical Sibling Peripheral Hematopietic Stem Cell Transplantation with or without Anti-Lymphocyte Globulin (ATG). Results from a Prospective, Multicenter Randomized Phase III Trial (ATGfamilystudy)
Authors: Francesca Bonifazi, Carlos Solano, Christine Wolschke, Francesca Patriarca, Massimo Pini, Arnon Nagler, Mino Selleri, Giuseppe Messina, Wolfgang A. Bethge, Pilar Herrera Fuente, Rafael F Duarte, Nicola Cascavilla, Michele Cimminiello, Stefano Guidi, Jürgen Finke, Andrea Gallamini, Christelle Ferrà, Jorge Sierra, Domenico Russo, Mario Petrini, Giuseppe Milone, Fabio Benedetti, Marion Heinzelmann, Vincenzo Liso, Manuel Jurado, Enrico Maria Pogliani, Franco Narni, Andreas Völp, Giuseppe Bandini, Francis Ayuk, Nicolaus Kröger
Journal: Blood (2014)
P2-076: The expression of anti-apoptotic protein, survivin, in non-small cell lung cancer
Authors: Fumihiko Hoshi, Chiaki Endo, Akira Sakurada, Yuji Matsumura, Yoshinori Okada, Yasushi Okada, Tetsu Sado, Masafumi Noda, Itaru Ishida, Takashi Kondo
Journal: Journal of Thoracic Oncology (2007)
Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation (allo-HCT) Provides Durable Progression-Free Survival (PFS) in a Subset of Diffuse Large B-Cell Lymphoma (DLBCL) Patients Relapsing after Autologous (auto-) HCT
Authors: Timothy S. Fenske, Tara M. Graff, Kwang Woo Ahn, Alyssa DiGilio, Sonali M. Smith, Anna Sureda, Mehdi Hamadani
Journal: Blood (2015)
B5-07: The effect of NQO1 polymorphisms on prognosis of non-small cell lung cancer after postoperative radiation therapy
Authors: Si Yeol Song, Eun Kyung Choi, Jung Shin Lee, Heon Joo Park, Sang-Wook Lee, Seung Il Park, Dong-Kwan Kim, Sang-We Kim, Dae Ho Lee, Yu Sun Lee
Journal: Journal of Thoracic Oncology (2007)
Clinical activity of anti-<i>programmed death-1</i> (PD-1) agents in acral and mucosal melanoma.
Authors: Rodrigo Ramella Munhoz, Alexander Noor Shoushtari, Deborah Kuk, Patrick Alexander Ott, Douglas Buckner Johnson, Katy K. Tsai, Suthee Rapisuwon, Zeynep Eroglu, Ryan J. Sullivan, Jason John Luke, Tara C. Gangadhar, April K. Salama, Varina Clark, Clare Burias, Igor Puzanov, Michael B. Atkins, Alain Patrick Algazi, Antoni Ribas, Jedd D. Wolchok, Michael Andrew Postow
Journal: Journal of Clinical Oncology (2016)

9516 Background: Antibodies against PD-1 resulted in a paradigm shift in the management of melanoma. Nevertheless, melanoma is a heterogeneous disease: compared to cutaneous melanoma, mucosal melanoma (MM) and acral melanoma (AM) have distinct genetic and clinical characteristics, lower somatic mutational burden, and poorer prognosis. We sought to investigate the efficacy of PD-1 blockade in patients (pts) with advanced mm and AM. Methods: We conducted a multicenter retrospective study of pts with advanced mm or AM treated with nivolumab or pembrolizumab. Clinical, pathologic, and treatment data were retrieved from electronic medical records. Response rates were assessed by RECIST v1.1 and survival intervals were calculated using the Kaplan-Meier method. Variables associated with response and survival were investigated. Results: Sixty pts were identified; 35 (58%) with mm and 25 (42%) with AM. Fifty-one (85%) pts had received prior therapy, including 77% with prior ipilimumab. Forty pts (67%) received pembrolizumab at 2mg/kg or 10mg/kg and 20 (33%) received nivolumab at 1mg/kg or 3mg/kg every 2-3 weeks. Objective response rate (ORR) (95% confidence interval) was 23% (10-40%) in mm and 32% (15-54%) in AM. ORR did not vary by age, primary site, or prior therapy outcomes. With a median follow-up of 10.6 months (mo) for mm and 20 mo for AM, the median progression-free survival was 3.9 mo and 4.1 mo, respectively. Median overall survival for the entire cohort was 16.8 mo; in mm it was 12.4 mo, and in AM 31.7 mo. Only two pts (3%) discontinued treatment due to toxicity. Conclusions: PD-1 blockade resulted in clinically meaningful activity in pts with mm and AM. Response rates and safety profile were comparable to published clinical trials which largely consisted of cutaneous melanoma and support the use of PD-1 blockade for mm and AM as well. The role of specific driver mutations, immunologic infiltrates and potential biomarkers of response and resistance in these melanoma subtypes needs further investigation.
Physical Inactivity Among Adults Aged 50 Years and Older — United States, 2014
Authors: Kathleen B. Watson, Susan A. Carlson, Janelle P. Gunn, Deborah A. Galuska, Ann O’Connor, Kurt J. Greenlund, Janet E. Fulton
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

Physical activity can help delay, prevent, or manage many of the chronic diseases for which adults aged ≥50 years are at risk (1-3). These diseases can impact the length and quality of life, as well as the long-term ability to live independently.* All adults aged ≥50 years, with or without chronic disease, gain health benefits by avoiding inactivity (2,3). To examine the prevalence of inactivity by selected demographic characteristics and chronic disease status in mid-life and older adults, CDC analyzed data on adults aged ≥50 years from the 2014 Behavioral Risk Factor Surveillance System (BRFSS). Overall, 27.5% of adults aged ≥50 years reported no physical activity outside of work during the past month. Inactivity prevalence significantly increased with increasing age and was 25.4% among adults aged 50-64 years, 26.9% among those aged 65-74 years, and 35.3% among those aged ≥75 years. Inactivity prevalence was significantly higher among women than men, among Hispanics and non-Hispanic blacks than among non-Hispanic whites, and among adults who reported ever having one or more of seven selected chronic diseases than among those not reporting one. Inactivity prevalence significantly increased with decreasing levels of education and increasing body mass index. To help adults with and without chronic disease start or maintain an active lifestyle, communities can implement evidence-based strategies, such as creating or enhancing access to places for physical activity, designing communities and streets to encourage physical activity, and offering programs that address specific barriers to physical activity.
P1-133: Epidemiologic and Clinicopathologic Characteristics of Malignant Mesothelioma through Surveillance System in Korea
Authors: Soon-Hee Jung, Yosep Chong, Hyoung-Ryul Kim, Yun-Kyung Chung, Sang-Baek Koh, Suk-Joong Yong, Tae-In Park, Myoung-Ja Chung, Yoon-Mee Kim, Ji-Sun Song
Journal: Journal of Thoracic Oncology (2007)
P0594 : Can serum level of hepatitis B surface antigen (HBsAg) differentiate HBsAg inactive carrier state from chronic hepatitis B?
Authors: M. Keshvari, S. Sali, H. Sharafi, S. Hoda Alavian, S. Moayed Alavian, F. Etesam, S. Salimi, M.A. Merza
Journal: Journal of Hepatology (2015)
Nedocromil sodium versus albuterol in the management of allergic asthma.
Authors: J W de Jong, J P Teengs, D S Postma, T W van der Mark, G H Koëter, J G de Monchy
Journal: American Journal of Respiratory and Critical Care Medicine (1994)

In a double-blind, double-placebo, randomized crossover study, we compared the effects of 6 wk of treatment with the anti-inflammatory drug nedocromil sodium (16 mg/day) with 6 wk of treatment with the bronchodilator drug albuterol (800 micrograms/day) in 29 adults with allergic asthma. After 3 and 6 wk of treatment with nedocromil sodium, patients were significantly less hyperresponsive to propranolol (p = 0.002 and p = 0.02) and almost significantly less hyperresponsive to histamine (p = 0.071 and p = 0.065). FEV1 and FVC percent predicted tended to be higher, morning PEF values increased significantly (p = 0.038 and p = 0.03), and diurnal and day-to-day PEF variation decreased (p = 0.03 and p = 0.093, p = 0.005 and p = 0.096, respectively) with nedocromil sodium treatment compared with albuterol treatment. Almost all symptoms (daytime and nighttime asthma, wheezing, shortness of breath) and the additional bronchodilator use were significantly reduced with nedocromil sodium treatment compared with albuterol treatment. Treatment with the anti-inflammatory drug nedocromil sodium was shown to be superior to treatment with the bronchodilator drug albuterol. The patient's clinical situation may deteriorate when beta 2-agonists are used continuously. Nedocromil sodium has good clinical effect, and it may serve as a first-line choice for antiinflammatory therapy in asthma.